A public offering of 1.9 million securities units has been priced by Rosetta Genomics in hopes of raising about $2.7 million. The proceeds will be used to support the company's operations and other general corporate functions.
Securities offering could pull in $2.7M for Rosetta Genomics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.